CS Group (OTCQB: CSDX) has taken a significant step in strengthening its financial oversight by appointing Shah Teelani & Associates, a Dubai-based PCAOB-registered audit firm, to consolidate and audit all 2025 financial statements for CS Diagnostics Corp., CS Interpharm GT LLC, and CS Diagnostics Pharma GmbH. The engagement reflects the company's commitment to regulatory compliance and transparent financial reporting as it expands into the United States, GCC region, and Europe.
The consolidated audit will cover operations related to the MEDUSA hygiene and disinfectant platform and international distribution expansion. By integrating its growing international subsidiaries under a unified reporting framework, CS Group aims to enhance financial clarity, streamline reporting processes, and bolster investor confidence. Management emphasized that appointing a PCAOB-registered auditor aligns the Group's financial reporting with U.S. public company standards.
Mohammad Essayed, Group Chief Financial Officer, stated: “Engaging Shah Teelani & Associates as our PCAOB-registered auditor represents an important milestone in CS Group’s evolution as a publicly traded company. As we scale operations across multiple regions, it is essential that our financial reporting structure reflects institutional-grade standards, transparency, and regulatory compliance. This appointment strengthens our governance foundation and supports our long-term growth strategy.”
CS Group continues to pursue manufacturing partnerships, regulatory approvals, international distribution agreements, and capital markets readiness. The company's forward-looking statements note risks and uncertainties, including market conditions, regulatory actions, and potential delays. For further information, visit https://group-csd.com/.
About CS Diagnostics Corp: CS Diagnostics Corp. (OTCQB: CSDX) is a medical technology company advancing infection control and oncology solutions. Its portfolio includes MEDUSA smart disinfectant and hygiene solutions and CS Protect-Hydrogel, a tissue spacer for prostate cancer radiotherapy. The company is progressing through key commercialization milestones, including strategic manufacturing partnerships, multi-region launches, and a growing intellectual property roadmap.
This announcement contains forward-looking statements subject to risks and uncertainties. Actual results may differ materially from those projected.
